Cargando…
Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
BACKGROUND: The protein 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a key stimulator of glycolytic flux. Systemic, partial PFKFB3 inhibition previously decreased total plaque burden and increased plaque stability. However, it is unclear which cell type conferred these positive...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387953/ https://www.ncbi.nlm.nih.gov/pubmed/34458258 http://dx.doi.org/10.3389/fcell.2021.695684 |
_version_ | 1783742549056290816 |
---|---|
author | Tillie, Renée J. H. A. De Bruijn, Jenny Perales-Patón, Javier Temmerman, Lieve Ghosheh, Yanal Van Kuijk, Kim Gijbels, Marion J. Carmeliet, Peter Ley, Klaus Saez-Rodriguez, Julio Sluimer, Judith C. |
author_facet | Tillie, Renée J. H. A. De Bruijn, Jenny Perales-Patón, Javier Temmerman, Lieve Ghosheh, Yanal Van Kuijk, Kim Gijbels, Marion J. Carmeliet, Peter Ley, Klaus Saez-Rodriguez, Julio Sluimer, Judith C. |
author_sort | Tillie, Renée J. H. A. |
collection | PubMed |
description | BACKGROUND: The protein 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a key stimulator of glycolytic flux. Systemic, partial PFKFB3 inhibition previously decreased total plaque burden and increased plaque stability. However, it is unclear which cell type conferred these positive effects. Myeloid cells play an important role in atherogenesis, and mainly rely on glycolysis for energy supply. Thus, we studied whether myeloid inhibition of PFKFB3-mediated glycolysis in Ldlr(–/–)LysMCre(+/–)Pfkfb3(fl/fl) (Pfkfb3(fl/fl)) mice confers beneficial effects on plaque stability and alleviates cardiovascular disease burden compared to Ldlr(–/–)LysMCre(+/–)Pfkfb3(wt/wt) control mice (Pfkfb3(wt/wt)). METHODS AND RESULTS: Analysis of atherosclerotic human and murine single-cell populations confirmed PFKFB3/Pfkfb3 expression in myeloid cells, but also in lymphocytes, endothelial cells, fibroblasts and smooth muscle cells. Pfkfb3(wt/wt) and Pfkfb3(fl/fl) mice were fed a 0.25% cholesterol diet for 12 weeks. Pfkfb3(fl/fl) bone marrow-derived macrophages (BMDMs) showed 50% knockdown of Pfkfb3 mRNA. As expected based on partial glycolysis inhibition, extracellular acidification rate as a measure of glycolysis was partially reduced in Pfkfb3(fl/fl) compared to Pfkfb3(wt/wt) BMDMs. Unexpectedly, plaque and necrotic core size, as well as macrophage (MAC3), neutrophil (Ly6G) and collagen (Sirius Red) content were unchanged in advanced Pfkfb3(fl/fl) lesions. Similarly, early lesion plaque and necrotic core size and total plaque burden were unaffected. CONCLUSION: Partial myeloid knockdown of PFKFB3 did not affect atherosclerosis development in advanced or early lesions. Previously reported positive effects of systemic, partial PFKFB3 inhibition on lesion stabilization, do not seem conferred by monocytes, macrophages or neutrophils. Instead, other Pfkfb3-expressing cells in atherosclerosis might be responsible, such as DCs, smooth muscle cells or fibroblasts. |
format | Online Article Text |
id | pubmed-8387953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83879532021-08-27 Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis Tillie, Renée J. H. A. De Bruijn, Jenny Perales-Patón, Javier Temmerman, Lieve Ghosheh, Yanal Van Kuijk, Kim Gijbels, Marion J. Carmeliet, Peter Ley, Klaus Saez-Rodriguez, Julio Sluimer, Judith C. Front Cell Dev Biol Cell and Developmental Biology BACKGROUND: The protein 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a key stimulator of glycolytic flux. Systemic, partial PFKFB3 inhibition previously decreased total plaque burden and increased plaque stability. However, it is unclear which cell type conferred these positive effects. Myeloid cells play an important role in atherogenesis, and mainly rely on glycolysis for energy supply. Thus, we studied whether myeloid inhibition of PFKFB3-mediated glycolysis in Ldlr(–/–)LysMCre(+/–)Pfkfb3(fl/fl) (Pfkfb3(fl/fl)) mice confers beneficial effects on plaque stability and alleviates cardiovascular disease burden compared to Ldlr(–/–)LysMCre(+/–)Pfkfb3(wt/wt) control mice (Pfkfb3(wt/wt)). METHODS AND RESULTS: Analysis of atherosclerotic human and murine single-cell populations confirmed PFKFB3/Pfkfb3 expression in myeloid cells, but also in lymphocytes, endothelial cells, fibroblasts and smooth muscle cells. Pfkfb3(wt/wt) and Pfkfb3(fl/fl) mice were fed a 0.25% cholesterol diet for 12 weeks. Pfkfb3(fl/fl) bone marrow-derived macrophages (BMDMs) showed 50% knockdown of Pfkfb3 mRNA. As expected based on partial glycolysis inhibition, extracellular acidification rate as a measure of glycolysis was partially reduced in Pfkfb3(fl/fl) compared to Pfkfb3(wt/wt) BMDMs. Unexpectedly, plaque and necrotic core size, as well as macrophage (MAC3), neutrophil (Ly6G) and collagen (Sirius Red) content were unchanged in advanced Pfkfb3(fl/fl) lesions. Similarly, early lesion plaque and necrotic core size and total plaque burden were unaffected. CONCLUSION: Partial myeloid knockdown of PFKFB3 did not affect atherosclerosis development in advanced or early lesions. Previously reported positive effects of systemic, partial PFKFB3 inhibition on lesion stabilization, do not seem conferred by monocytes, macrophages or neutrophils. Instead, other Pfkfb3-expressing cells in atherosclerosis might be responsible, such as DCs, smooth muscle cells or fibroblasts. Frontiers Media S.A. 2021-08-12 /pmc/articles/PMC8387953/ /pubmed/34458258 http://dx.doi.org/10.3389/fcell.2021.695684 Text en Copyright © 2021 Tillie, De Bruijn, Perales-Patón, Temmerman, Ghosheh, Van Kuijk, Gijbels, Carmeliet, Ley, Saez-Rodriguez and Sluimer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Tillie, Renée J. H. A. De Bruijn, Jenny Perales-Patón, Javier Temmerman, Lieve Ghosheh, Yanal Van Kuijk, Kim Gijbels, Marion J. Carmeliet, Peter Ley, Klaus Saez-Rodriguez, Julio Sluimer, Judith C. Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis |
title | Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis |
title_full | Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis |
title_fullStr | Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis |
title_full_unstemmed | Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis |
title_short | Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis |
title_sort | partial inhibition of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (pfkfb3) enzyme in myeloid cells does not affect atherosclerosis |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387953/ https://www.ncbi.nlm.nih.gov/pubmed/34458258 http://dx.doi.org/10.3389/fcell.2021.695684 |
work_keys_str_mv | AT tilliereneejha partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT debruijnjenny partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT peralespatonjavier partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT temmermanlieve partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT ghoshehyanal partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT vankuijkkim partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT gijbelsmarionj partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT carmelietpeter partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT leyklaus partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT saezrodriguezjulio partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis AT sluimerjudithc partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis |